|Articles|December 1, 2000

New Approaches for the Diagnosis and Management of Alzheimer's Disease
Volume 6
Issue 22 Suppl

The Pharmacoeconomics of Alzheimer's Disease

Author(s)Howard Fillit, MD

Download PDF: The Pharmacoeconomics of Alzheimer's Disease

Articles in this issue

almost 26 years ago

Article

Participating Faculty

almost 26 years ago

Article

Introduction

almost 26 years ago

Article

Screening and Early Diagnosis of Dementia

almost 26 years ago

Article

Alzheimer's Disease: Clinical Treatment Options

almost 26 years ago

Article

Managed Care Decisions in Alzheimer's Disease

almost 26 years ago

Article

Conflicting Priorities in Alzheimer's Care, Primary Care, and Managed Care: Who Pays the Price?

almost 26 years ago

Article

Continuing Medical Education Quiz

almost 26 years ago

Article

Selected Abstracts

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

ByAayush Sisodia, MSHI, BDS

Published: August 6th 2026 | Updated: August 31st 2026

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

The Pharmacoeconomics of Alzheimer's Disease

Articles in this issue

Related Content

Predicting GLP-1 Discontinuation From Pharmacy Claims

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Trending on AJMC

Multiagonists Outpace Older GLP-1 Drugs for Weight Loss

Inside Myeloma’s Evolution From Death Sentence to Cure

Evolocumab Cuts Death Risk for a First Heart Attack or Stroke

Better Cardiovascular Health Tied to Lower Overactive Bladder Risk

FDA Approves Ropeginterferon Alfa-2b in Essential Thrombocythemia